Skip to main navigation menu Skip to main content Skip to site footer
##common.pageHeaderLogo.altText##

Original article

Vol. 151 No. 4950 (2021)

Smartphone-based active vaccine safety surveillance (SmartVax) at a Swiss adult vaccination clinic – a pilot study

  • Daniela S. Guedel
  • Ian J. Peters
  • Florian Banderet
  • Varenka Epple
  • Sabine Egli
  • Matthias Mehling
  • Michael Mayr
  • Alan Leeb
  • Christoph T. Berger
DOI
https://doi.org/10.4414/SMW.2021.w30090
Cite this as:
Swiss Med Wkly. 2021;151:w30090
Published
14.12.2021

Summary

INTRODUCTION: Post-licensure surveillance of adverse events following immunisation (AEFI) is critical for detecting rare but severe AEFI. SmartVax software, using smartphone technology, actively solicits reports of AEFI via automated, opt-out SMS surveys to vaccine recipients in the days following immunisation. We report on a pilot study to test the feasibility and acceptance of SmartVax in Switzerland.

METHODS: Between February and September 2020, consecutive subjects immunised at an adult immunisation clinic and the employee health service at the University Hospital of Basel were screened. Participants included three subgroups: healthcare workers (HCW), subjects with immune-mediated inflammatory diseases (IMID) and clients of the regular adult immunisation clinic. Three days after vaccination, participants received an SMS inquiring if they had any AEFI. In the case of an AEFI, subjects received an automated SMS with a link to an online survey assessing the type and temporal evolution of the AEFI. Descriptive statistics of response rate, time-to-response, frequency and type of AEFI by vaccine and clinical subgroup were performed.

RESULTS: Of 293 subjects screened, 276 were included (46.6% routine vaccination check-up visits, 33.3% HCW, 20.1% IMID patients) receiving 625 vaccinations during 360 immunisation visits. The SMS response rate was high (90.3%), with a median time-to-respond of 47 minutes (interquartile range11–205). After 29.8% of immunisation visits at least one AEFI was reported. There were no differences in frequency or type of AEFI between the three clinical subgroups. The recombinant, adjuvanted zoster vaccine Shingrix® was associated with the highest rate of local and systemic reactions.

CONCLUSION: Monitoring post-licensure vaccine safety using the active SMS-based surveillance system SmartVax is feasible in Switzerland. We observed a high acceptance in the diverse study population, including healthcare workers and IMID patients. High response rates in the elderly and reliable monitoring almost in real-time make SmartVax a promising tool for COVID-19 vaccine safety monitoring.

References

  1. Braun MM, Ellenberg SS. Descriptive epidemiology of adverse events after immunization: reports to the Vaccine Adverse Event Reporting System (VAERS), 1991-1994. J Pediatr. 1997 Oct;131(4):529–35. https://doi.org/10.1016/S0022-3476(97)70056-8
  2. Zhou W, Pool V, Iskander JK, English-Bullard R, Ball R, Wise RP, et al. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)—United States, 1991-2001. MMWR Surveill Summ. 2003 Jan;52(1):1–24.
  3. Ahmadipour N, Watkins K, Fréchette M, Coulby C, Anyoti H, Johnson K. Vaccine safety surveillance in Canada: reports to CAEFISS, 2013-2016. Can Commun Dis Rep. 2018 Sep;44(9):206–14. https://doi.org/10.14745/ccdr.v44i09a04
  4. McNeil MM, DeStefano F. Vaccine-associated hypersensitivity. J Allergy Clin Immunol. 2018 Feb;141(2):463–72. https://doi.org/10.1016/j.jaci.2017.12.971
  5. Mutsch M, Zhou W, Rhodes P, Bopp M, Chen RT, Linder T, et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell’s palsy in Switzerland. N Engl J Med. 2004 Feb;350(9):896–903. https://doi.org/10.1056/NEJMoa030595
  6. Barker CI, Snape MD. Pandemic influenza A H1N1 vaccines and narcolepsy: vaccine safety surveillance in action. Lancet Infect Dis. 2014 Mar;14(3):227–38. https://doi.org/10.1016/S1473-3099(13)70238-X
  7. Fescharek R, Nicolay U, Arras-Reiter C. Monitoring and safety assessment in Phase I to III clinical trials. Dev Biol Stand. 1998;95:203–9.
  8. Bonhoeffer J, Kohl K, Chen R, Duclos P, Heijbel H, Heininger U, et al.; The Brighton Collaboration. The Brighton Collaboration: addressing the need for standardized case definitions of adverse events following immunization (AEFI). Vaccine. 2002 Dec;21(3-4):298–302. https://doi.org/10.1016/S0264-410X(02)00449-8
  9. Di Pasquale A, Bonanni P, Garçon N, Stanberry LR, El-Hodhod M, Tavares Da Silva F. Vaccine safety evaluation: practical aspects in assessing benefits and risks. Vaccine. 2016 Dec;34(52):6672–80. https://doi.org/10.1016/j.vaccine.2016.10.039
  10. Crawford NW, Clothier H, Hodgson K, Selvaraj G, Easton ML, Buttery JP. Active surveillance for adverse events following immunization. Expert Rev Vaccines. 2014 Feb;13(2):265–76. https://doi.org/10.1586/14760584.2014.866895
  11. Hazell L, Shakir SA. Under-reporting of adverse drug reactions : a systematic review. Drug Saf. 2006;29(5):385–96. https://doi.org/10.2165/00002018-200629050-00003
  12. Monteiro SA, Takano OA, Waldman EA. [Evaluation of the Brazilian surveillance system for adverse events following vaccination]. Rev Bras Epidemiol. 2011 Sep;14(3):361–71. https://doi.org/10.1590/S1415-790X2011000300002
  13. Clothier HJ, Selvaraj G, Easton ML, Lewis G, Crawford NW, Buttery JP. Consumer reporting of adverse events following immunization. Hum Vaccin Immunother. 2014;10(12):3726–30. https://doi.org/10.4161/hv.34369
  14. Centers of Disease Control and Prevention. Vaccine Adverse Event Reporting System (VAERS). 2017, January 27 2020, April 8]; Available from: https://www.cdc.gov/vaccinesafety/ensuringsafety/monitoring/vaers/index.html
  15. Hasford J, Goettler M, Munter KH, Müller-Oerlinghausen B. Physicians’ knowledge and attitudes regarding the spontaneous reporting system for adverse drug reactions. J Clin Epidemiol. 2002 Sep;55(9):945–50. https://doi.org/10.1016/S0895-4356(02)00450-X
  16. Isaacs D, Lawrence G, Boyd I, Ronaldson K, McEwen J. Reporting of adverse events following immunization in Australia. J Paediatr Child Health. 2005 Apr;41(4):163–6. https://doi.org/10.1111/j.1440-1754.2005.00580.x
  17. Rosenthal S, Chen R. The reporting sensitivities of two passive surveillance systems for vaccine adverse events. Am J Public Health. 1995 Dec;85(12):1706–9. https://doi.org/10.2105/AJPH.85.12.1706
  18. Salathé M, Khandelwal S. Assessing vaccination sentiments with online social media: implications for infectious disease dynamics and control. PLOS Comput Biol. 2011 Oct;7(10):e1002199. https://doi.org/10.1371/journal.pcbi.1002199
  19. Salathé M, Vu DQ, Khandelwal S, Hunter DR. The dynamics of health behavior sentiments on a large online social network. EPJ Data Sci. 2013;2(1):4. https://doi.org/10.1140/epjds16
  20. Salathé M. Digital Pharmacovigilance and Disease Surveillance: Combining Traditional and Big-Data Systems for Better Public Health. J Infect Dis. 2016 Dec;214 suppl_4:S399–403. https://doi.org/10.1093/infdis/jiw281
  21. Freifeld CC, Brownstein JS, Menone CM, Bao W, Filice R, Kass-Hout T, et al. Digital drug safety surveillance: monitoring pharmaceutical products in twitter. Drug Saf. 2014 May;37(5):343–50. https://doi.org/10.1007/s40264-014-0155-x
  22. Thoon KC, Soh SB, Liew WK, Gunachandran A, Tan NW, Chong CY, et al. Active surveillance of adverse events following childhood immunization in Singapore. Vaccine. 2014 Sep;32(39):5000–5. https://doi.org/10.1016/j.vaccine.2014.07.020
  23. Sebastian J, Gurumurthy P, Ravi MD, Ramesh M. Active surveillance of adverse events following immunization (AEFI): a prospective 3-year vaccine safety study. Ther Adv Vaccines Immunother. 2019 Nov;7:2515135519889000. https://doi.org/10.1177/2515135519889000
  24. Spila Alegiani S, Alfonsi V, Appelgren EC, Ferrara L, Gallo T, Alicino C, et al. Active surveillance for safety monitoring of seasonal influenza vaccines in Italy, 2015/2016 season. BMC Public Health. 2018 Dec;18(1):1401. https://doi.org/10.1186/s12889-018-6260-5
  25. Pillsbury A, Quinn H, Cashman P, Leeb A, Macartney K ; AusVaxSafety consortium. Active SMS-based influenza vaccine safety surveillance in Australian children. Vaccine. 2017 Dec;35(51):7101–6. https://doi.org/10.1016/j.vaccine.2017.10.091
  26. Wilson K, Atkinson KM, Westeinde J, Bell C, Marty K, Fergusson D, et al. An evaluation of the feasibility and usability of a proof of concept mobile app for adverse event reporting post influenza vaccination. Hum Vaccin Immunother. 2016 Jul;12(7):1738–48. https://doi.org/10.1080/21645515.2016.1152434
  27. Nguyen MT, Ott JJ, Caputo M, Keller-Stanislawski B, Klett-Tammen CJ, Linnig S, et al. User preferences for a mobile application to report adverse events following vaccination. Pharmazie. 2020 Jan;75(1):27–31.
  28. Westphal DW, Williams SA, Leeb A, Effler PV. Continuous active surveillance of adverse events following immunisation using SMS technology. Vaccine. 2016 Jun;34(29):3350–5. https://doi.org/10.1016/j.vaccine.2016.05.015
  29. Regan AK, Blyth CC, Tracey L, Mak DB, Richmond PC, Effler PV. Comparison of text-messaging to voice telephone interviews for active surveillance of adverse events following immunisation. Vaccine. 2015 Jul;33(31):3689–94. https://doi.org/10.1016/j.vaccine.2015.06.022
  30. Stockwell MS, Marchant CD, Wodi AP, Barnett ED, Broder KR, Jakob K, et al. A multi-site feasibility study to assess fever and wheezing in children after influenza vaccines using text messaging. Vaccine. 2017 Dec;35(50):6941–8. https://doi.org/10.1016/j.vaccine.2017.10.073
  31. Leeb A, Regan AK, Peters IJ, Leeb C, Leeb G, Effler PV. Using automated text messages to monitor adverse events following immunisation in general practice. Med J Aust. 2014 Apr;200(7):416–8. https://doi.org/10.5694/mja13.11166
  32. Pillsbury A, Cashman P, Leeb A, Regan A, Westphal D, Snelling T, et al.; AusVaxSafety, surveillance team. Real-time safety surveillance of seasonal influenza vaccines in children, Australia, 2015. Euro Surveill. 2015;20(43). https://doi.org/10.2807/1560-7917.ES.2015.20.43.30050
  33. Bonhoeffer J, Bentsi-Enchill A, Chen RT, Fisher MC, Gold MS, Hartman K, et al.; Brighton Collaboration Methods Working Group. Guidelines for collection, analysis and presentation of vaccine safety data in pre- and post-licensure clinical studies. Vaccine. 2009 Apr;27(16):2282–8. https://doi.org/10.1016/j.vaccine.2008.11.036
  34. Bonhoeffer J, Imoukhuede EB, Aldrovandi G, Bachtiar NS, Chan ES, Chang S, et al.; Brighton Collaboration Clinical Trial Protocol Working Group. Template protocol for clinical trials investigating vaccines—focus on safety elements. Vaccine. 2013 Nov;31(47):5602–20. https://doi.org/10.1016/j.vaccine.2013.02.041
  35. Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang SJ, et al.; ZOE-50 Study Group. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015 May;372(22):2087–96. https://doi.org/10.1056/NEJMoa1501184
  36. Cunningham AL, Lal H, Kovac M, Chlibek R, Hwang SJ, Díez-Domingo J, et al.; ZOE-70 Study Group. Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older. N Engl J Med. 2016 Sep;375(11):1019–32. https://doi.org/10.1056/NEJMoa1603800
  37. Diaz GA, Parsons GT, Gering SK, Meier AR, Hutchinson IV, Robicsek A. Myocarditis and Pericarditis After Vaccination for COVID-19. JAMA. 2021 Sep;326(12):1210–2. https://doi.org/10.1001/jama.2021.13443
  38. Bozkurt B, Kamat I, Hotez PJ. Myocarditis With COVID-19 mRNA Vaccines. Circulation. 2021 Aug;144(6):471–84. https://doi.org/10.1161/CIRCULATIONAHA.121.056135
  39. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al.; COVE Study Group. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021 Feb;384(5):403–16. https://doi.org/10.1056/NEJMoa2035389
  40. Cook IF. Sex differences in injection site reactions with human vaccines. Hum Vaccin. 2009 Jul;5(7):441–9. https://doi.org/10.4161/hv.8476
  41. Harris T, Nair J, Fediurek J, Deeks SL. Assessment of sex-specific differences in adverse events following immunization reporting in Ontario, 2012-15. Vaccine. 2017 May;35(19):2600–4. https://doi.org/10.1016/j.vaccine.2017.03.035
  42. Mok CC, Ho LY, Fong LS, To CH. Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus: a case-control study. Ann Rheum Dis. 2013 May;72(5):659–64. https://doi.org/10.1136/annrheumdis-2012-201393
  43. Hatz C, Beck B, Steffen R, Genton B, d’Acremont V, Loutan L, et al. Real-life versus package insert: a post-marketing study on adverse-event rates of the virosomal hepatitis A vaccine Epaxal® in healthy travellers. Vaccine. 2011 Jul;29(31):5000–6. https://doi.org/10.1016/j.vaccine.2011.04.099
  44. López-Fauqued M, Campora L, Delannois F, El Idrissi M, Oostvogels L, De Looze FJ, et al.; ZOE-50/70 Study Group. Safety profile of the adjuvanted recombinant zoster vaccine: pooled analysis of two large randomised phase 3 trials. Vaccine. 2019 Apr;37(18):2482–93. https://doi.org/10.1016/j.vaccine.2019.03.043
  45. Oldenburg J, Klamroth R, Langer F, Albisetti M, von Auer C, Ay C, et al. Diagnosis and Management of Vaccine-Related Thrombosis following AstraZeneca COVID-19 Vaccination: guidance Statement from the GTH. Hamostaseologie. 2021 Jun;41(3):184–9. https://doi.org/10.1055/a-1469-7481

Most read articles by the same author(s)

1 2 > >>